Role of TWEAK in lupus nephritis: A bench-to-bedside review

Journal of Autoimmunity

Volumn 39, Issue 3, 2012, Pages 130-142

  Michaelson, Jennifer S ^a   Wisniacki, Nicolas ^b   Burkly, Linda C ^a   Putterman, Chaim ^c  

^a BIOGEN   (United States)

^b Medical Research   (United Kingdom)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Fn14; Lupus nephritis; SLE; TWEAK

Indexed keywords

BIIB 023; CREATININE; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

APOPTOSIS; CELL PROLIFERATION; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; VASCULARIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; CELL PROLIFERATION; CLINICAL TRIALS, PHASE II AS TOPIC; FIBROSIS; GENE EXPRESSION; HUMANS; KIDNEY GLOMERULUS; KIDNEY TUBULES; LUPUS NEPHRITIS; MOLECULAR TARGETED THERAPY; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 84865391444     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.05.003     Document Type: Review

References (150)

1. Borchers A.T., Aoki C.A., Naguwa S.M., Keen C.L., Shoenfeld Y., Gershwin M.E. Neuropsychiatric features of systemic lupus erythematosus. Autoimmun Rev 2005, 4:329-344.
2. Cameron J.S. Lupus nephritis. J Am Soc Nephrol 1999, 10:413-424.
3. Dooley M.A., Jayne D., Ginzler E.M., Isenberg D., Olsen N.J., Wofsy D., et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011, 365:1886-1895.
4. Ioannidis J.P., Boki K.A., Katsorida M.E., Drosos A.A., Skopouli F.N., Boletis J.N., et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000, 57:258-264.
5. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003, 82:299-308.
6. Korbet S.M., Lewis E.J., Schwartz M.M., Reichlin M., Evans J., Rohde R.D. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000, 35:904-914.
7. Chan T.M., Tse K.C., Tang C.S., Lai K.N., Li F.K. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005, 14:265-272.
8. Chen Y.E., Korbet S.M., Katz R.S., Schwartz M.M., Lewis E.J., Collaborative Study G. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol: CJASN 2008, 3:46-53.
9. Houssiau F.A., Vasconcelos C., D'Cruz D., Sebastiani G.D., Garrido Ede R., Danieli M.G., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46:2121-2131.
10. Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzova D., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930.
11. Appel G.B., Contreras G., Dooley M.A., Ginzler E.M., Isenberg D., Jayne D., et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20:1103-1112.
12. Badsha H., Edwards C.J. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003, 32:370-377.
13. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52:501-513.
14. Waldman M., Appel G.B. Update on the treatment of lupus nephritis. Kidney Int 2006, 70:1403-1412.
15. Cook H.T., Botto M. Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006, 2:330-337.
16. Nangaku M., Couser W.G. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 2005, 9:183-191.
17. Austin H.A., Muenz L.R., Joyce K.M., Antonovych T.A., Kullick M.E., Klippel J.H., et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983, 75:382-391.
18. Hsieh C., Chang A., Brandt D., Guttikonda R., Utset T.O., Clark M.R. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 2011, 63:865-874.
19. Mok C.C. Prognostic factors in lupus nephritis. Lupus 2005, 14:39-44.
20. Chicheportiche Y., Bourdon P.R., Xu H., Hsu Y.M., Scott H., Hession C., et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997, 272:32401-32410.
21. Desplat-Jego S., Varriale S., Creidy R., Terra R., Bernard D., Khrestchatisky M., et al. TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 2002, 133:116-123.
22. Donohue P.J., Richards C.M., Brown S.A., Hanscom H.N., Buschman J., Thangada S., et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003, 23:594-600.
23. Justo P., Sanz A.B., Sanchez-Nino M.D., Winkles J.A., Lorz C., Egido J., et al. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 2006, 70:1750-1758.
24. van Kuijk A.W., Wijbrandts C.A., Vinkenoog M., Zheng T.S., Reedquist K.A., Tak P.P. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to TNF blockade. Ann Rheum Dis 2010, 69:301-304.
25. Kawashima R., Kawamura Y.I., Oshio T., Son A., Yamazaki M., Hagiwara T., et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. Gastroenterology 2011, 141:2119-2129.
26. Serafini B., Magliozzi R., Rosicarelli B., Reynolds R., Zheng T.S., Aloisi F. Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury. J Neuropathol Exp Neurol 2008, 67:1137-1148.
27. Hotta K., Sho M., Yamato I., Shimada K., Harada H., Akahori T., et al. Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int 2011, 79:179-188.
28. Sanz A.B., Justo P., Sanchez-Nino M.D., Blanco-Colio L.M., Winkles J.A., Kreztler M., et al. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 2008, 19:695-703.
29. Lu J., Kwan B.C., Lai F.M., Choi P.C., Tam L.S., Li E.K., et al. Gene expression of TWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. Nephrology 2011, 16:426-432.
30. Schwartz N., Rubinstein T., Burkly L.C., Collins C.E., Blanco I., Su L., et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009, 11:R143.
31. Schwartz N., Su L., Burkly L.C., Mackay M., Aranow C., Kollaros M., et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006, 27:242-250.
32. Bover L.C., Cardo-Vila M., Kuniyasu A., Sun J., Rangel R., Takeya M., et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007, 178:8183-8194.
33. Fick A., Lang I., Schafer V., Seher A., Trebing J., Weisenberger D., et al. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem 2012, 287:484-495.
34. Gao H.X., Campbell S.R., Burkly L.C., Jakubowski A., Jarchum I., Banas B., et al. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokines 2009, 46:24-35.
35. Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425.
36. Burkly L.C., Dohi T. The TWEAK/Fn14 pathway in tissue remodeling: for better or for worse. Adv Exp Med Biol 2011, 691:305-322.
37. Dohi T., Borodovsky A., Wu P., Shearstone J.R., Kawashima R., Runkel L., et al. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology 2009, 136:912-923.
38. Chorianopoulos E., Heger T., Lutz M., Frank D., Bea F., Katus H.A., et al. FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol 2010, 105:301-313.
39. Munoz-Garcia B., Moreno J.A., Lopez-Franco O., Sanz A.B., Martin-Ventura J.L., Blanco J., et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 2009, 29:2061-2068.
40. Wiley S.R., Cassiano L., Lofton T., Davis-Smith T., Winkles J.A., Lindner V., et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001, 15:837-846.
41. Girgenrath M., Weng S., Kostek C.A., Browning B., Wang M., Brown S.A., et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. Embo J 2006, 25:5826-5839.
42. Mittal A., Bhatnagar S., Kumar A., Paul P.K., Kuang S. Genetic ablation of TWEAK augments regeneration and post-injury growth of skeletal muscle in mice. Am J Pathol 2010, 177:1732-1742.
43. Desplat-Jego S., Creidy R., Varriale S., Allaire N., Luo Y., Bernard D., et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol 2005, 117(1):15-23.
44. Potrovita I., Zhang W., Burkly L., Hahm K., Lincecum J., Wang M.Z., et al. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 2004, 24:8237-8244.
45. Yepes M., Brown S.A., Moore E.G., Smith E.P., Lawrence D.A., Winkles J.A. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 2005, 166:511-520.
46. Jakubowski A., Ambrose C., Parr M., Lincecum J.M., Wang M.Z., Zheng T.S., et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest 2005, 115:2330-2340.
47. Tirnitz-Parker J.E., Viebahn C.S., Jakubowski A., Klopcic B.R., Olynyk J.K., Yeoh G.C., et al. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology 2010, 52:291-302.
48. Michaelson J.S., Burkly L.C. Therapeutic targeting of TWEAK/Fn14 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ 2009, 49:145-160.
49. Saitoh T., Nakayama M., Nakano H., Yagita H., Yamamoto N., Yamaoka S. TWEAK induces NF-kB2 p100 processing and long-lasting NF-kB activation. J Biol Chem 2003, 278:36005-36012.
50. Campbell S., Burkly L.C., Gao H.X., Berman J.W., Su L., Browning B., et al. Proinflammatory effects of tweak/fn14 interactions in glomerular mesangial cells. J Immunol 2006, 176:1889-1898.
51. Izquierdo M.C., Sanz A.B., Mezzano S., Blanco J., Carrasco S., Sanchez-Nino M.D., et al. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int 2012, 81:1098-1107.
52. Sanz A.B., Sanchez-Nino M.D., Izquierdo M.C., Jakubowski A., Justo P., Blanco-Colio L.M., et al. Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med 2009, 13:3329-3342.
53. Sanz A.B., Sanchez-Nino M.D., Izquierdo M.C., Jakubowski A., Justo P., Blanco-Colio L.M., et al. TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One 2010, 5:e8955.
54. Burkly L.C., Michaelson J.S., Zheng T.S. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 2011, 244:99-114.
55. Chicheportiche Y., Chicheportiche R., Sizing I., Thompson J., Benjamin C.B., Ambrose C., et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002, 4:126-133.
56. Hosokawa Y., Hosokawa I., Ozaki K., Nakae H., Matsuo T. Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol 2006, 146:540-549.
57. Harada N., Nakayama M., Nakano H., Fukuchi Y., Yagita H., Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002, 299:488-493.
58. Kim S.H., Kang Y.J., Kim W.J., Woo D.K., Lee Y., Kim D.I., et al. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004, 68:396-399.
59. Jin L., Nakao A., Nakayama M., Yamaguchi N., Kojima Y., Nakano N., et al. Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J Invest Dermatol 2004, 122:1175-1179.
60. Perper S.J., Browning B., Burkly L.C., Weng S., Gao C., Giza K., et al. TWEAK is a novel arthritogenic mediator. J Immunol 2006, 177:2610-2620.
61. Xu H., Okamoto A., Ichikawa J., Ando T., Tasaka K., Masuyama K., et al. TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem Biophys Res Commun 2004, 318:422-427.
62. Saas P., Boucraut J., Walker P.R., Quiquerez A.L., Billot M., Desplat-Jego S., et al. TWEAK stimulation of astrocytes and the proinflammatory consequences. GLIA 2000, 32:102-107.
63. Jakubowski A., Browning B., Lukashev M., Sizing I., Thompson J.S., Benjamin C.D., et al. Dual role for TWEAK in angiogenic regulation. J Cell Sci 2002, 115:267-274.
64. Lynch C.N., Wang Y.C., Lund J.K., Chen Y.W., Leal J.A., Wiley S.R. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999, 274:8455-8459.
65. Polavarapu R., Gongora M.C., Winkles J.A., Yepes M. Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation. J Neurosci 2005, 25:10094-10100.
66. Burkly L.C., Michaelson J.S., Hahm K., Jakubowski A., Zheng T.S. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007, 40:1-16.
67. Bhatnagar S., Mittal A., Gupta S.K., Kumar A. TWEAK causes myotube atrophy through coordinated activation of ubiquitin-proteasome system, autophagy, and caspases. Cell Physiol 2012, 227:1042-1051.
68. Dogra C., Hall S.L., Wedhas N., Linkhart T.A., Kumar A. Fibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes. Evidence for TWEAK-independent functions of Fn14 during myogenesis. J Biol Chem 2007, 282:15000-15010.
69. Haile WB, Echeverry R, Wu F, Guzman J, An J, Wu J et al. Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death. Neuroscience;171:1256-64.
70. Jain M., Jakubowski A., Cui L., Shi J., Su L., Bauer M., et al. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 2009, 119:2058-2068.
71. Vincent C., Findlay D.M., Welldon K.J., Wijenayaka A.R., Zheng T.S., Haynes D.R., et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009, 24:1434-1449.
72. Novoyatleva T., Diehl F., van Amerongen M.J., Patra C., Ferrazzi F., Bellazzi R., et al. TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res 2010, 85:681-690.
73. Zhi-Chun L., Qiao-Ling Z., Zhi-Qin L., Xiao-Zhao L., Xiao-Xia Z., Rong T. Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) mediates p38 mitogen-activated protein kinase activation and signal transduction in peripheral blood Mononuclear cells from patients with lupus nephritis. Inflammation 2012, 35:935-943.
74. Wang C., Chen L.L., Pan H.F., Leng R.X., Qin W.Z., Ye D.Q. Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus. Clin Rheumatol 2012, 31:335-339.
75. El-Shehaby A., Darweesh H., El-Khatib M., Momtaz M., Marzouk S., El-Shaarawy N., et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 2011, 31:848-856.
76. Lopez-Novoa J.M., Rodriguez-Pena A.B., Ortiz A., Martinez-Salgado C. Lopez Hernandez FJ. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. J Transl Med 2011, 9:13.
77. Zhao Z., Burkly L.C., Campbell S., Schwartz N., Molano A., Choudhury A., et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007, 179:7949-7958.
78. Xia Y.C.S., Herlitz L., Michaelson J.S., Burkly L.C., Putterman C. TWEAK/Fn14 pathway blockade attenuates renal disease in autoantibody-induced nephritis. American College of Rheumatology 75th Natl Meeting. Arthritis Rheum 2011, 63:S212.
79. Xia Y.W.J., Michaelson J.S., Burkly L.C., Putterman C. Deficiency of the TWEAK receptor Fn14 is protective in the MRL/lpr mouse model of lupus nephritis. American College of Rheumatology 75th Natl Meeting. Arthritis Rheum 2011, 63:S212.
80. Hill G.S., Delahousse M., Nochy D., Remy P., Mignon F., Mery J.P., et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 2001, 59:304-316.
81. Appel G.B., Pirani C.L., D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994, 4:1499-1515.
82. Garin E.H., West L., Zheng W. Effect of interleukin-8 on glomerular sulfated compounds and albuminuria. Pediatr Nephrol 1997, 11:274-279.
83. Garin E.H., West L., Zheng W. Interleukin-8 alters glomerular heparan sulfate glycosaminoglycan chain size and charge in rats. Pediatr Nephrol 2000, 14:284-287.
84. Nagai M., Hirayama K., Ebihara I., Higuchi T., Imaizumi M., Maruyama H., et al. Serum TNF-related and weak inducer of apoptosis levels in septic shock patients. Ther Apher Dial 2011, 15:342-348.
85. Duffield J.S., Humphreys B.D. Origin of new cells in the adult kidney: results from genetic labeling techniques. Kidney Int 2011, 79:494-501.
86. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011, 7:684-696.
87. Chen G., Lin S.C., Chen J., He L., Dong F., Xu J., et al. CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis. J Am Soc Nephrol 2011, 22:1876-1886.
88. Korbet S.M., Schwartz M.M., Evans J., Lewis E.J. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007, 18:244-254.
89. Contreras G., Pardo V., Cely C., Borja E., Hurtado A., De La Cuesta C., et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005, 14:890-895.
90. Mok C.C., Ho C.T., Chan K.W., Lau C.S., Wong R.W. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002, 46:1003-1013.
91. Austin H.A., Boumpas D.T., Vaughan E.M., Balow J.E. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995, 10:1620-1628.
92. Praga M. Therapeutic measures in proteinuric nephropathy. Kidney Int Suppl 2005, S137-S141.
93. Praga M., Morales E. Renal damage associated with proteinuria. Kidney Int Suppl 2002, S42-S46.
94. Hebert L.A., Wilmer W.A., Falkenhain M.E., Ladson-Wofford S.E., Nahman N.S., Rovin B.H. Renoprotection: one or many therapies?. Kidney Int 2001, 59:1211-1226.
95. Donadio J.V., Hart G.M., Bergstralh E.J., Holley K.E. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995, 4:109-115.
96. Korbet S.M., Lewis E.J., for the Collaborative Study Group Complete remission in severe lupus nephritis: assessing the rate of loss in proteinuria. Nephrol Dial Transplant 2011 Dec 23, [Epub ahead of print].
97. Markowitz G.S., D'Agati V.D. Classification of lupus nephritis. Curr Opin Nephrol Hypertens 2009, 18:220-225.
98. Austin H.A., Muenz L.R., Joyce K.M., Antonovych T.T., Balow J.E. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984, 25:689-695.
99. Conlon P.J., Fischer C.A., Levesque M.C., Smith S.R., St Clair E.W., Allen N.B., et al. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol 1996, 46:170-175.
100. Cortes-Hernandez J., Ordi-Ros J., Labrador M., Segarra A., Tovar J.L., Balada E., et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003, 12:287-296.
101. Kanno A., Hotta O., Yusa N., Taguma Y. Predictive factors of clinical outcome in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy. Ren Fail 2007, 29:41-47.
102. Yadav A., Saini V., Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta: Int J Clin Chem 2010, 411:1570-1579.
103. Kulkarni O., Eulberg D., Selve N., Zollner S., Allam R., Pawar R.D., et al. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. J Pharmacol Exp Ther 2009, 328:371-377.
104. Kulkarni O., Pawar R.D., Purschke W., Eulberg D., Selve N., Buchner K., et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007, 18:2350-2358.
105. Perez D.L., Maier H., Nieto E., Vielhauer V., Luckow B., Mampaso F., et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 2001, 12:1369-1382.
106. Shimizu S., Nakashima H., Masutani K., Inoue Y., Miyake K., Akahoshi M., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology 2004, 43:1121-1128.
107. Tesch G.H., Schwarting A., Kinoshita K., Lan H.Y., Rollins B.J., Kelley V.R. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest 1999, 103(1):73-80.
108. Rovin B.H., Song H., Birmingham D.J., Hebert L.A., Yu C.Y., Nagaraja H.N. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005, 16:467-473.
109. Kiani A.N., Johnson K., Chen C., Diehl E., Hu H., Vasudevan G., et al. Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J Rheumatol 2009, 36:2224-2230.
110. Alzawawy A., Zohary M., Ablordiny M., Eldalie M. Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis. Int J Rheum Dis 2009, 12:311-318.
111. Marks S.D., Shah V., Pilkington C., Tullus K. Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. Pediatr Nephrol 2010, 25:2283-2288.
112. Brunner H.I., Bennett M.R., Mina R., Suzuki M., Petri M., Kiani A.N., et al. Non-invasive renal protein biomarkers are associated with histological features of lupus nephritis. Arthritis Rheum 2012 Feb 10, [Epub ahead of print].
113. Zhang X., Nagaraja H.N., Nadasdy T., Song H., McKinley A., Prosek J., et al. A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int 2012, 81:401-406.
114. Perez de Lema G., Maier H., Franz T.J., Escribese M., Chilla S., Segerer S., et al. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J Am Soc Nephrol 2005, 16:3592-3601.
115. Moore K.J., Wada T., Barbee S.D., Kelley V.R. Gene transfer of RANTES elicits autoimmune renal injury in MRL-Fas(1pr) mice. Kidney Int 1998, 53:1631-1641.
116. Xie C., Zhou X.J., Liu X., Mohan C. Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain. Arthritis Rheum 2003, 48:1080-1092.
117. Tian S., Li J., Wang L., Liu T., Liu H., Cheng G., et al. Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflamm Res Off J Eur Histamine Res Soc 2007, 56:304-310.
118. Fu Q., Chen X., Cui H., Guo Y., Chen J., Shen N., et al. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Therapy 2008, 10:R112.
119. Liao C.H., Yao T.C., Chung H.T., See L.C., Kuo M.L., Huang J.L. Polymorphisms in the promoter region of RANTES and the regulatory region of monocyte chemoattractant protein-1 among Chinese children with systemic lupus erythematosus. J Rheumatol 2004, 31:2062-2067.
120. Ye D.Q., Yang S.G., Li X.P., Hu Y.S., Yin J., Zhang G.Q., et al. Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus. Arch Dermatol Res 2005, 297:108-113.
121. Reyes-Thomas J., Blanco I., Putterman C. Urinary biomarkers in lupus nephritis. Clin Rev Allergy Immunol 2011, 40:138-150.
122. Yap D.Y., Lai K.N. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 2010, 2010:365083.
123. Tackey E., Lipsky P.E., Illei G.G. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004, 13:339-343.
124. Finck B.K., Chan B., Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994, 94:585-591.
125. Mihara M., Takagi N., Takeda Y., Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998, 112:397-402.
126. Ryffel B., Car B.D., Gunn H., Roman D., Hiestand P., Mihatsch M.J. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol 1994, 144:927-937.
127. Cash H., Relle M., Menke J., Brochhausen C., Jones S.A., Topley N., et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol 2010, 37:60-70.
128. Lu L.D., Stump K.L., Wallace N.H., Dobrzanski P., Serdikoff C., Gingrich D.E., et al. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J Immunol 2011, 187:3840-3853.
129. Herrera-Esparza R., Barbosa-Cisneros O., Villalobos-Hurtado R., Avalos-Diaz E. Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus 1998, 7:154-158.
130. Iwano M., Dohi K., Hirata E., Kurumatani N., Horii Y., Shiiki H., et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol 1993, 40:16-21.
131. Tsai C.Y., Wu T.H., Yu C.L., Lu J.Y., Tsai Y.Y. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000, 85:207-214.
132. Santos M.J., Fernandes D., Capela S., da Silva J.C., Fonseca J.E. Interleukin-6 promoter polymorphism -174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients. Clin Rheumatol 2011, 30:409-413.
133. Illei G.G., Shirota Y., Yarboro C.H., Daruwalla J., Tackey E., Takada K., et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542-552.
134. Neville L.F., Mathiak G., Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997, 8:207-219.
135. Vielhauer V., Anders H.J., Schlondorff D. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin Nephrol 2007, 27:81-97.
136. Romagnani P., Beltrame C., Annunziato F., Lasagni L., Luconi M., Galli G., et al. Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J Am Soc Nephrol 1999, 10:2518-2526.
137. Liu J., Karypis G., Hippen K.L., Vegoe A.L., Ruiz P., Gilkeson G.S., et al. Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun 2006, 7:156-168.
138. Avihingsanon Y., Phumesin P., Benjachat T., Akkasilpa S., Kittikowit V., Praditpornsilpa K., et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int 2006, 69:747-753.
139. Segerer S., Banas B., Wornle M., Schmid H., Cohen C.D., Kretzler M., et al. CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis. Am J Pathol 2004, 164:635-649.
140. Enghard P., Humrich J.Y., Rudolph B., Rosenberger S., Biesen R., Kuhn A., et al. CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum 2009, 60:199-206.
141. Wu T., Xie C., Wang H.W., Zhou X.J., Schwartz N., Calixto S., et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007, 179:7166-7175.
142. Nakatani K., Fujii H., Hasegawa H., Terada M., Arita N., Ito M.R., et al. Endothelial adhesion molecules in glomerular lesions: association with their severity and diversity in lupus models. Kidney Int 2004, 65:1290-1300.
143. Molad Y., Miroshnik E., Sulkes J., Pitlik S., Weinberger A., Monselise Y. Urinary soluble VCAM-1 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage. Clin Exp Rheumatol 2002, 20:403-406.
144. Abd-Elkareem M.I., Al Tamimy H.M., Khamis O.A., Abdellatif S.S., Hussein M.R. Increased urinary levels of the leukocyte adhesion molecules ICAM-1 and VCAM-1 in human lupus nephritis with advanced renal histological changes: preliminary findings. Clin Exp Nephrol 2010, 14:548-557.
145. Wisniacki N.C., Vishala L., Codding C.E. Phase I, randomized, double-blind, placebo-controlled, single dose, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of BIIB023 (Anti-TWEAK) in subjects with rheumatoid arthritis. Arthritis Rheum 2011, 63-68.
146. Kapsogeorgou E.K., Gourzi V.C., Manoussakis M.M., Moutsopoulos H.M., Tzioufas A.G. Cellular microrNAs (miRNAs) and Sjogren's syndrome: candidate regulators of autoimmune response and autoantigen expression. J Autoimmun 2011, 37:129-135.
147. Rose N.R. The genetics of autoimmune thyroiditis: the first decade. J Autoimmun 2011, 37:88-94.
148. Scheinecker C., Bonelli M., Smolen J.S. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun 2010, 35:269-275.
149. Youinou P., Haralampos M. Moutsopoulos: a lifetime in autoimmunity. J Autoimmun 2010, 35:171-175.
150. Miyagawa F., Gutermuth J., Zhang H., Katz S.I. The use of mouse models to better understand mechanisms of autoimmunity and tolerance. J Autoimmun 2010, 35:192-198.